MX2019010042A - Compuesto de tres ciclos y aplicaciones del mismo. - Google Patents

Compuesto de tres ciclos y aplicaciones del mismo.

Info

Publication number
MX2019010042A
MX2019010042A MX2019010042A MX2019010042A MX2019010042A MX 2019010042 A MX2019010042 A MX 2019010042A MX 2019010042 A MX2019010042 A MX 2019010042A MX 2019010042 A MX2019010042 A MX 2019010042A MX 2019010042 A MX2019010042 A MX 2019010042A
Authority
MX
Mexico
Prior art keywords
applications
tri
cycle compound
compound
cycle
Prior art date
Application number
MX2019010042A
Other languages
English (en)
Inventor
Wang Jing
He Haiying
Chen Shuhui
Jiang Zhigan
Yang Yaxun
Shao Peng
Zhang Chen
Li Jian
Original Assignee
Fujian Cosunter Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujian Cosunter Pharmaceutical Co Ltd filed Critical Fujian Cosunter Pharmaceutical Co Ltd
Publication of MX2019010042A publication Critical patent/MX2019010042A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen en la presente invención un compuesto representado por la Fórmula (I), un tautómero del mismo o una sal farmacéuticamente aceptable del mismo, y aplicaciones de los mismos en la preparación de fármacos para tratar enfermedades relacionadas con VHB. (ver fórmula I).
MX2019010042A 2017-02-23 2018-02-09 Compuesto de tres ciclos y aplicaciones del mismo. MX2019010042A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201710100309 2017-02-23
CN201710648155 2017-08-01
CN201810008592 2018-01-04
PCT/CN2018/075995 WO2018153285A1 (zh) 2017-02-23 2018-02-09 三并环类化合物及其应用

Publications (1)

Publication Number Publication Date
MX2019010042A true MX2019010042A (es) 2020-01-13

Family

ID=63253508

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010042A MX2019010042A (es) 2017-02-23 2018-02-09 Compuesto de tres ciclos y aplicaciones del mismo.

Country Status (23)

Country Link
US (1) US11053260B2 (es)
EP (1) EP3587420B1 (es)
JP (1) JP6764039B2 (es)
KR (1) KR102085497B1 (es)
CN (1) CN109071544B (es)
AU (1) AU2018223435B2 (es)
BR (1) BR112019017603A2 (es)
CA (1) CA3054324C (es)
DK (1) DK3587420T3 (es)
ES (1) ES2874656T3 (es)
HU (1) HUE054822T2 (es)
IL (1) IL268827A (es)
LT (1) LT3587420T (es)
MX (1) MX2019010042A (es)
MY (1) MY175445A (es)
PH (1) PH12019501955A1 (es)
PL (1) PL3587420T3 (es)
PT (1) PT3587420T (es)
RS (1) RS61913B1 (es)
SG (1) SG11201907725SA (es)
SI (1) SI3587420T1 (es)
WO (1) WO2018153285A1 (es)
ZA (1) ZA201906135B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112334137A (zh) * 2018-05-03 2021-02-05 埃默里大学 用于nash和其他代谢紊乱的孤儿核受体调节剂
JP7118354B2 (ja) 2018-08-23 2022-08-16 福建▲広▼生中霖生物科技有限公司 三環式化合物の結晶形及びその使用
CN110172068A (zh) * 2019-06-05 2019-08-27 河南龙湖生物技术有限公司 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用
US20220306648A1 (en) * 2019-08-15 2022-09-29 Fujian Akeylink Biotechnology Co., Ltd. Preparation Method for Oxazepine Compound
WO2021213445A1 (zh) * 2020-04-22 2021-10-28 南京明德新药研发有限公司 内磺酰胺衍生物及其应用
CN115515596A (zh) * 2020-05-15 2022-12-23 福建广生中霖生物科技有限公司 包含三并环类化合物的组合及其在制备治疗hbv药物中的应用
CN114456099A (zh) * 2022-02-21 2022-05-10 八叶草健康产业研究院(厦门)有限公司 一种4-氯吡咯-2-羧酸的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2443703C2 (ru) 2007-06-18 2012-02-27 Саншайн Лейк Фарма Ко., Лтд Бром-фенил замещенные тиазолилдигидропиримидины
CN102060786A (zh) 2011-01-20 2011-05-18 天津大学 4-(取代-1,3-二炔基)-4-(三氟甲基)-3,4-二氢取代喹唑啉-2-酮类化合物及其制备方法和应用
ES2640063T3 (es) 2013-04-03 2017-10-31 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
ES2777248T3 (es) 2013-11-14 2020-08-04 Novira Therapeutics Inc Derivados de azepano y métodos de tratar infecciones por hepatitis B
RS59430B1 (sr) 2014-03-13 2019-11-29 Univ Indiana Res & Tech Corp Alosterni modulatori proteina jezgra hepatitisa b
WO2015173164A1 (en) 2014-05-13 2015-11-19 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
TWI721016B (zh) * 2015-09-15 2021-03-11 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
EP3366684B1 (en) 2015-10-23 2020-09-02 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3512845A1 (en) 2016-09-15 2019-07-24 Assembly Biosciences, Inc. Hepatitis b core protein modulators

Also Published As

Publication number Publication date
CN109071544B (zh) 2020-03-17
CA3054324A1 (en) 2018-08-30
LT3587420T (lt) 2021-07-12
EP3587420A1 (en) 2020-01-01
SG11201907725SA (en) 2019-09-27
RS61913B1 (sr) 2021-06-30
JP2020508342A (ja) 2020-03-19
KR102085497B1 (ko) 2020-03-05
PT3587420T (pt) 2021-06-04
HUE054822T2 (hu) 2021-10-28
AU2018223435A1 (en) 2019-10-10
DK3587420T3 (da) 2021-06-07
AU2018223435B2 (en) 2020-12-24
KR20190120300A (ko) 2019-10-23
IL268827A (en) 2019-11-03
EP3587420B1 (en) 2021-03-31
SI3587420T1 (sl) 2021-09-30
CA3054324C (en) 2020-12-01
ZA201906135B (en) 2021-04-28
US20200247819A1 (en) 2020-08-06
ES2874656T3 (es) 2021-11-05
US11053260B2 (en) 2021-07-06
CN109071544A (zh) 2018-12-21
JP6764039B2 (ja) 2020-09-30
PH12019501955A1 (en) 2020-07-06
WO2018153285A1 (zh) 2018-08-30
PL3587420T3 (pl) 2021-10-11
BR112019017603A2 (pt) 2020-03-24
EP3587420A4 (en) 2020-02-19
MY175445A (en) 2020-06-29

Similar Documents

Publication Publication Date Title
PH12018550120A1 (en) Steroid derivative fxr agonist
PH12019501955A1 (en) Tri-cycle compound and applications thereof
PH12019501688A1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
ZA202202097B (en) Amino pyrimidine ssao inhibitors
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
PH12019500480A1 (en) Pyridine compound
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
MY194116A (en) Pharmaceutical compounds
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
PH12016502246B1 (en) Carboxamide derivatives
TN2016000491A1 (en) Carboxamide derivatives.
MX2019010108A (es) Derivados de azetidina.
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
EA201991910A1 (ru) Трициклическое соединение и пути его применения
EA038580B9 (ru) Агонист fxr, представляющий собой производное стероидов
PH12016502247A1 (en) Carboxamide derivatives